Objective The inhibitory effect of the PARP inhibitor olaparib on human acute myeloid leukemia HL-60 cells was studied. Methods The HL-60 cells in logarithmic growth phase were treated with different concentrations(1. 25,2. 5,5 and 10 μmol/L) of olaparib for different time. The CCK-8 assay was used to detect the inhibitory effect of olaparib on HL-60 cells. The apoptotic level of HL-60 cells was detected by Annexin-V/PI double staining method,and the expression of related signal proteins ( PARP-1 and caspase-3)in HL-60 cells was detected by Western blot. Results HL-60 cells were inhibited by olaparib at dif-ferent concentrations(1. 25,2. 5,5 and 10 μmol/L) for 48 h,and the inhibition rate gradually increased with the prolongation of the action time;at the same time,the apoptotic rate was increased in HL-60 cells after olaparib treatment for 48 h,showing a dose-de-pendent manner;the PARP activity was inhibited and caspase-3 was activated in HL-60 cells treated with olaparib. Conclusion The PARP inhibitor olaparib not only inhibits proliferation of HL-60 cells,but it also promotes apoptosis of HL-60 cells by inhibi-ting PARP activity and activating caspase-3.

Objective This study aimed to investigate the relationship between CLPTM1L gene and lung cancer 95-D cells sensitivity to gemcitabine,and to explore its potential mechanism of action. Methods Overexpression of lentivirus against CLPTM1L gene was constructed and infected with lung cancer 95-D cells;Cells were divided into the CLPTM1L overexpression group and con-trol group;The proliferation of cells in the overexpressing and control groups after gemcitabine treatment was detected by CCK-8;The changes of CLPTM1L gene and protein were detected by real-time PCR,Western blot and immunochemiluminescence;The changes of caspase-3/7 and caspase-9 activities were detected by bioluminescence;Western blot was used to detect the changes of p-4E-BP1 protein. Results The expression of CLPTM1L gene( P =0. 036) and its protein ( P <0. 01) was significantly increased after CLPTM1L overexpressed lentivirus-infected 95 -D cells;Compared with the control group,the proliferation of CLPTM1L overex-pressing group after gemcitabine treatment was increased(P <0. 01);The activity of caspase activity showed that the activities of caspase-3/7 and caspase-9 in the CLPTM1L overexpression group were significantly lower than those in the control group(P<0. 01);The phosphorylated level of 4E-BP1 protein in the CLPTM1L overexpression group was significantly higher than that in the control group. Conclusion Overexpression of CLPTM1L can reduce the sensitivity of lung cancer cells to gemcitabine. Its mechanism may be to increase the phosphorylation level of 4E-BP1.

Objective The aim of this study was to observe the expression of human epidermal growth factor receptor( EG-FR),epidermal growth factor receptor 2(HER2)and epidermal growth factor receptor 3(HER3)in cholangiocarcinoma(CCA),and to explore the relationship between the expression of EGFR,HER2,HER3 and the clinicopathological features,overall survival time and proliferation of CCA patients. Methods Fifty patients with CCA who underwent surgery in our hospital from January 2009 to October 2013 were enrolled,and their adjacent tissues were also collected as controls. Immunohistochemistry and qRT-PCR were used to de-tect the expression of EGFR,HER2 and HER3 in CCA and adjacent tissues. The clinicopathological parameters of patients were col-lected and the relationship between EGFR,HER2,and HER3 expression and clinicopathological parameters of CCA was analyzed. Ka-plan-Meier survival curves were plotted,and the relationship between the expression of EGFR,HER2,and HER3 and total postopera-tive survival of 50 patients with CCA was analyzed using the Log-rank test and Cox proportional hazard model. The expression of EG-FR,HER2 and HER3 in CCA QBC939 cell line was knocked down by RNA interference assay. The knockdown effect of EGFR,HER2 and HER3 was detected by Western blot. The effect of EGFR,HER2 and HER3 on proliferation of QBC939 cells was determined by MTT assay. Results The positive expression of EGFR,HER2 and HER3 was determined in CCA tissues. The relationship analysis of clinicopathological characteristics showed that the HER2 expression was associated with CCA lymph node metastasis(P<0. 05). EG-FR and HER3 was associated with CCA lymph node metastasis and correlated with cancer differentiation(P<0. 05). The overall sur-vival of patients with EGFR,HER2 and HER3 positive was significantly lower than that of negative patients( P<0. 05). After knoc-king EGFR,HER2 and HER3 expression,the proliferation was significantly decreased in QBC939 cells(P<0. 05). Conclusion The expression of EGFR,HER2 and HER3 in CCA tissues is closely related to the overall survival of patients,and the mechanism may be related to the promotion of proliferation of CCA cells.

Objective The aim of this study was to investigate the role and mechanism of ABL2 in lung cancer and its mech-anism. Methods The expression of ABL2 in lung cancer and adjacent tissues was detected by Real-Time PCR. A lung adenocarci-noma A549 cell line stably expressing of ABL2 was established,and the changes of cell proliferation and migration ability were detec-ted by MTT,cell migration and colony formation assays. Western blot was used to detect the expression of EMT,apoptosis and PI3K/AKT signaling pathway-related proteins. Results The expression of ABL2 in lung cancer tissues was significantly higher than that in adjacent tissues(P<0. 001). After silencing ABL2 in the A549 cells,compared with the control group,the migration ability of cells was weakened after 48 hours(P<0. 001),the growth rate of cells began to slow down from the third day(P<0. 05),and the average number of clones formed after 15 days also decreased(P<0. 01). The expression of E-cadherin( P<0. 001) was increased in the epithelial cell marker after silencing ABL2,and the expression of stromal cell markers N -cadherin ( P <0. 001),Vimentin ( P <0. 01)and Snail(P<0. 001)was decreased. The expression of apoptosis-related protein Bcl-XL(P<0. 01)was decreased and BAX ( P<0. 001)expression was up-regulated. The expression of PI3K/AKT signaling pathway-associated proteins such as PI3K P110 (P<0. 05),AKT(P<0. 01) and p-AKT( P<0. 05) was significantly decreased. Conclusion Silencing ABL2 gene can promote apoptosis,and inhibit proliferation and migration of lung cancer cells through a PI3K/AKT signaling pathway.

Objective The aim of this study was to investigate the effect and mechanism of pterostilbene on apoptosis and glycolysis of ovarian cancer SKOV3 cells. Methods SKOV3 cells were treated with 0,25,50,100 and 150 μmol/L of pterostilbene for 24,48 and 72 hours. The proliferation of SKOV3 cells was measured by CCK. The effect of pterostilbene on apoptosis of SKOV3 cells was determined by flow cytometry. The glucose consumption and lactate production were detected by glucose oxidase assay and chemical colorimetry. The expression of signal transducer and activator of transcription 3 ( STAT3 ), phosphorylated STAT3 ( p -STAT3) and hexokinase 2 ( HK2) proteins was detected by Western blot. The expression of glucose transporter 1 ( GLUT1) and M2 pyruvate kinase(PKM2)mRNA was detected by qRT-PCR. Results Pterostilbene inhibited the proliferation of SKOV3 cells in a time- and dose-dependent manner. According to CCK-8 results,100 μmol/L of pterostilbene was selected as the follow-up ex-perimental group and 0 μmol/L as a control group. Pterostilbene could significantly promote the apoptosis of SKOV3 cells in a dose-dependent manner. The higher the concentration,the more obvious apoptosis effect,the difference was statistically significant ( P <0. 05). In addition,the levels of glucose consumption and lactate production in the 100 μmol/L group were significantly lower than those in the 0 μmol/L group(P<0. 01). The expression of p-STAT3 and HK2 protein in the 100 μmol/L group was also significant-ly lower than those in the 0 μmol/L group(P<0. 001). The expression of GLUT1and PKM2 mRNA in the 100 μmol/L group was also significantly decreased than those in the 0 μmol/L group(P<0. 01). Conclusion Pterostilbene can inhibit the proliferation of SK-OV3 cells and promote apoptosis,and may inhibit the glycolysis of ovarian cancer through a STAT3/HK2 pathway.

Objective The objective of this study was to investigate the clinical value of serum microRNA in predicting chemotherapy efficacy in patients with nasopharyngeal carcinoma. Methods A total of 187 patients with nasopharyngeal carcinoma who received cisplatin combined chemotherapy were enrolled in our hospital from January 2010 to December 2016,including 123 pa-tients with chemotherapy sensitivity and 64 patients with chemotherapy resistance. The serum levels of miRNA before the initial chem-otherapy were measured,the efficacy and predictive value of serum miRNA in nasopharyngeal carcinoma patients were evaluated using healthy subjects as controls. Results Serum level of miR-127 in nasopharyngeal carcinoma patients was significantly higher than that in healthy controls(4. 3 ± 1. 6 vs. 1. 4 ± 0. 5,P<0. 001). Serum level of miR-127 was significantly higher in chemotherapy-resistant patients than that in chemotherapy-sensitive patients(4. 5 ± 1. 3 vs. 3. 8 ± 1. 7,P<0. 001). The ROC curve showed that the predictive value of serum miR-127 for chemotherapy resistance in nasopharyngeal carcinoma patients was 0. 702(P<0. 001), with the optimal cut-off value of 4. 2,sensitivity of 82. 3% and specificity of 76. 3% . Compared with the chemotherapy-sensitive group,the proportion of patients with T3-4 ,N3 and TNM Ⅲ~Ⅳ in the chemotherapy-resistant group was significantly increased(P<0. 01),and the proportion of miR-127≥4. 2 was also increased(P<0. 001). Multivariate logistic regression analysis showed that TNM staging(OR=1. 655,95% CI:1. 142~2. 584,P=0. 016)and serum miR-127≥4. 2(OR=2. 231,95% CI:1. 762~4. 503,P=0. 001)were independent risk factors affecting chemotherapy resistance in nasopharyngeal carcinoma patients. Conclusion The el-evated serum level of miR-127 is an important risk factor for predicting chemotherapy resistance in patients with nasopharyngeal car-cinoma.

Objective The objective of this study was to investigate the relationship between serum long-chain non-cod-ing RNA MALAT1 and AFAP1-AS1 and clinicopathological features,and prognosis of nasopharyngeal carcinoma(NPC). Methods A total of 136 patients with nasopharyngeal carcinoma confirmed by pathology in our hospital were selected from April 2013 to June 2015. During the same time,54 outpatients for health examination in our hospital were selected as the control group and nasopharynge-al carcinoma group. Real-time fluorescence reverse transcription analysis was used to analyze the expression of lncRNA MALAT1 and AFP1-AS1. The relationship between the expression of lncRNA MALAT1 and AFP1-AS1,and clinicopathological characteris-tics was analyzed by χ2 test. Log-rank assay was used to analyze serum long-chain non-coding RNA MALAT1 and prognostic differences in patients with different expression levels of AFAP1-AS1. Results Compared with the control group,the serum levels of RNA MALAT1 and RNA AFAP1-AS1 in the nasopharyngeal carcinoma group were significantly increased(P<0. 001);The expres-sions of lncRNA MALAT1 and AFAP1-AS1 was not related to age(P>0. 05);The maximum diameter of the tumor was≥5 cm,the pathological stage was higher,the TNM stage was higher,the deeper in the infiltration depth,the infiltration of lymphatic vessels,the lymph node metastasis,and the recurrence and the higher in high expressive rates of lncRNA MALAT1 and AFAP1 -AS1 ( P <0. 05). The 2-year survival rate and survival time of lncRNA MALAT1 and AFAP1-AS1 in the low expression group were signifi-cantly higher than those of the high expression group(P<0. 001);Multivariate Cox stepwise regression analysis showed that low ex-pression of lncRNA MALAT1(HR=0. 52,95% CI:0. 37~0. 81)and low expression of lncRNA AFAP1-AS1(HR=0. 56,95% CI:0. 51~0. 83)were independent prognostic protective factors for NPC patients(P<0. 001). Conclusion The serum long-chain non-coding RNA MALAT1 and AFAP1-AS1 are elevated in patients with NPC,and are positively correlated with malignant progression of NPC. NPC patients with low expression of lncRNA MALAT1 and AFAP1-AS1 serum have a good prognosis;MALAT1 and AFAP1 -AS1 can be used as new markers for the diagnosis of nasopharyngeal carcinoma.

Objective This article retrospectively analyzed the efficacy,toxicity,survival and related factors affecting progno-sis of patients with small cell lung cancer(SCLC)who had recurrence or progression after first-course chemoradiotherapy. Methods A total of 86 patients with recurrence or progression recurrence after SCLC chemotherapy and radiotherapy from January 2007 to De-cember 2015 in Harbin Medical University Cancer Hospital were enrolled. Patients were divided into the re-treatment group to re-ceive secondary treatment with radiotherapy combined with chemotherapy and two control groups to receive secondary treatment with radiotherapy alone or chemotherapy alone. The factors affecting the prognosis of SCLC re-treatment were analyzed. The short-term and long-term efficacy,overall survival and toxicity of three groups were compared. Results The median progression-free survival time of the re-treatment group,radiotherapy group,and chemotherapy alone group was 4 months(1~20 months),2 months(1 ~7 months)and 3 months(1~6 months). There was no statistical difference(P>0. 05). The median overall survival time was 25 months (3~135 months)in the re-treatment group and 8 months in the radiotherapy group(1-59 months)and 12 months(1~108)in the chemotherapy alone group,the difference was statistically significant ( P <0. 05 ). The 1 -,2 -,and 3 -year survival rates were 73. 70% ,52. 10% and 47. 40% in the re - treatment group; 32. 90% 、 21. 90% and 21. 90% in the radiotherapy group, and 45. 40% ,19. 90% and 19. 90% in the chemotherapy alone group. The long-term effect of the re-treatment group was better than that of the radiotherapy group and the chemotherapy alone group(P<0. 05). Conclusion Re-treatment of patients with SCLC who failed after receiving radiotherapy and chemotherapy for the first time can prolong the survival time of patients and improve the life quality of patients. If the patient's physical condition permits,the treatment should be selective radiotherapy and chemotherapy as well as tolerable toxicity or side effects. Among them,patients with no distant metastasis and recurrent radiotherapy dose ≥5 000 cGy had greater survival benefit. However,the late toxic and side effects,and complications of patients after re-treatment are still to be further observed.

Objective The objective of this study was to investigate the expression of microtubule associated protein 1A (MAP1A)in bladder cancer and its correlation with clinicopathological features. Methods One hundred and thirty seven cases of bladder cancer and adjacent tissues were collected. qRT -PCR and immunohistochemistry were used to analyze the expression of MAP1A in bladder cancer and adjacent tissues. The relationship between the expression of MAP1A and clinicopathological parameters& prognosis of bladder cancer patients was studied. Results The results of qRT-PCR showed that the expression level of MAP1A in 20 cases of bladder cancer was significantly lower than that of the matched adjacent tissues(t=5. 022,P<0. 001). The results of im-munohistochemistry also showed that the positive expression rates of MAP1A in bladder cancer and adjacent tissues were 46. 71% (46/37)and 79. 56% (109/137),respectively,and the difference was statistically significant(χ2 =23. 52,P<0. 0001). The expres-sion of MAP1A was closely related to clinical T stage,lymph node metastasis and TNM stage(χ2 =9. 982,P=0. 0016;χ2 =8. 064,P=0. 0045;χ2 =7. 199,P<0. 0073). Kaplan-Meier survival analysis showed that the overall survival(OS)and disease-free survival (DFS)of patients with low expression of MAP1A were significantly shorter than those with high expression of MAP1A(χ2 =26. 74,P<0. 0001;χ2 =18. 73,P<0. 0001). Cox multivariate regression analysis showed that TNM stage(HR=1. 46,P=0. 038)and MAP1A expression(HR=1. 213,P =0. 030) were independent risk factors for adverse prognosis of bladder cancer patients. Conclusion MAP1A is significantly down-regulated in bladder cancer tissues and is closely related to clinical TNM staging. The low expression of MAP1A may indicate the poor prognosis of bladder cancer patients.

Objective Dual-source CT(DSCT) energy imaging was used to analyze the difference of energy spectrum pa-rameters and energy spectrum curves between mediastinal metastatic lymph nodes and non-metastatic lymph nodes in non-small cell lung cancer(NSCLC). The relationship between DSCT standardized iodine concentration and energy spectrum curve with medias-tinal lymph node metastasis was discussed. Methods A total of 113 patients with NSCLC underwent DSCT energy imaging scans. Io-dine images were obtained at the processing workstation. The normalized iodine concentrations of all mediastinal lymph nodes and en-ergy spectrum curves at different energy levels were measured. According to the pathological results,the patients were divided into lymph node metastasis group and non-lymph node metastasis group. The normalized iodine concentration and energy spectrum curve slope of the two groups were analyzed by t-test. The best threshold of standardized working iodine concentration was calculated by re-ceiver operating characteristic curve(ROC)to diagnose the mediastinal lymph node metastasis of NSCLC. Results There was a sig-nificant difference in the normalized iodine concentration between the two groups of mediastinal lymph nodes in NSCLC(P<0. 05);The ROC curve was used to calculate the standardized iodine concentration for the diagnosis of NSCLC. The optimal threshold for lymph node metastasis was 52. 45% ;The energy spectrum curve of mediastinal lymph nodes in NSCLC was gradually decreasing. There was a significant difference between the two groups in the range of 40~110 keV interval(P<0. 05). Conclusion The quanti-tative analysis of DSCT energy imaging parameters is of great significance in the diagnosis of mediastinal lymph node metastasis in NSCLC. It can be used as an important index for preoperative judgment of lymph node metastasis in NSCLC.